

NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 17 Oct 2022 (#39)

[Click on blue hyperlink for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: <u>cdevries@sun.ac.za</u> ● Stellenbosch Campus <u>lizelk@sun.ac.za</u>

To prepare an application can take 4-18 months, depending on many factors:

- 1. Mechanism for which you will apply e.g. U54, R01, D43, K43
- 2. Requirement of preliminary data
- 3. Time to assemble the research team
- 4. Time available to work on the grant, taking into consideration other responsibilities
- 5. Time for internal review

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- PA-20-185 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- PA-20-184 Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- PA-20-183 Research Project Grant (Parent R01 Clinical Trial Required)
- PA-20-200 NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- PA-20-195 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- PA-20-194 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- <u>PA-20-196</u> NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Important Notices

<u>Gearing Up for Transition to FORMS-H Application Forms</u>: As <u>announced</u> over the summer, NIH requires the use of updated application forms (FORMS-H) for due dates on or after January 25, 2023. We will begin adding FORMS-H application packages to active funding opportunity announcements and FORMS-H application form instructions to the <u>How to Apply – Application Guide</u> page as early as October 25 to prepare for the transition.

The intended due date for your application determines the correct form version to use.

- DO use FORMS-G form version for application due dates on or before January 24, 2023
- DO use FORMS-H form version for application due dates on or after January 25, 2023
- DO NOT use FORMS-H too early or FORMS-G too late

NOT-NS-23-030 Notice of Intent to Publish a Notice of Special Interest (NOSI) for Efficacy Trials of Epidural Stimulation for Spinal Cord Injury. The National Institute of Neurological Disorders and Stroke intends to publish a Notice of Special Interest for applications proposing qualifying clinical trials to study epidural stimulation in spinal cord

injury. This notice is only for applications submitted to PAR-21-237 NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required) Funding Opportunity Announcement.

Funding Opportunity Announcements (FOA)

BRAIN Initiative: Brain-Behavior Quantification and Synchronization - Transformative and Integrative Models of Behavior at the Organismal Level (R34 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: RFA-DA-23-030 Type: R34 Application Due Date: February 14, 2023. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) seeks applications with limited scope proposing a set of planning activities that will lay the groundwork for a scientific project aimed at integrating complementary theories and methods to 1) develop, validate, and apply cutting-edge tools and methods for minimally invasive, multi-dimensional, high-resolution measurement of behavior at the level of the organism, with synchronous capture of changes in the organism's social or physical environment; and/or 2) develop computational methods that allow for integration of multidimensional behavioral and environmental data representing multiple timescales into a conceptual and/or computational model of behavior as a complex dynamic system, designed with the capacity to integrate synchronously recorded neural data and/or inform existing models of neurobehavioral function, such as those developed with the support of the NIH BRAIN Initiative. The purpose of this FOA is to support planning and development of the research framework, design, and approach, including activities that will

Budget: Application budgets should reflect the actual needs of the proposed project. The combined budget for direct costs for the two-year project period may not exceed \$450,000. No more than \$225,000 may be requested in any single year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

establish feasibility, validity, and/or other technically qualifying results that, if successful, would support a competitive application for a UO1,

2. Development of Novel Nonsteroidal Contraceptive Methods (R61/R33 - Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

R01 or equivalent NIH research award.

Hyperlink: RFA-HD-24-002 Type: R61/R33

Application Due Date: March 29, 2023. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is to support and facilitate multidisciplinary research approaches for the development of novel nonsteroidal contraceptive products for men and women that act prior to fertilization. This FOA aims to position innovative and validated methods for future clinical development.

Budget: The NICHD intends to commit \$3.0 million in FY 2024 to fund at least seven awards. For the R61 phase, Direct Costs may not exceed \$250,000 per year. For the R33 phase, Direct Costs may not exceed \$500,000 per year. The scope of the proposed project should determine the project period. The maximum project period of the combined R61 and R33 phases is up to 5 years with up to 2 years for the R61 phase and up to 3 years for the R33 phase. Applications with a project period of less than 5 years are encouraged where feasible.